CLINICAL_TRIALS
trial_result
· 2014-05-09
Clinical Trial Update: Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma [Phase 2]
Summary
Phase 2 study evaluating IPH2101 in patients with smoldering multiple myeloma has completed; results were posted in May 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Innate Pharma | Conditions: Smoldering Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-05-09